Odyssey Group International, Inc. (OTC: ODYY↑) was formed as a publicly held holding company with an emphasis on the development and acquisition of medical devices and health related technologies. The corporate mission is to acquire distinct assets, intellectual property, and technologies with an emphasis on acquisition targets that are under-valued and can be enhanced by our company internally or through strategic partnerships. Our goal is to deliver financial results, which yield high rates of returns for our shareholders and partners. The Company’s senior management team and leadership have significant experience and capabilities to further refine the acquired technologies, build commercial systems and/or create strategic partnerships.
Odyssey Board of Directors
Odyssey Group International, Inc.’s Board of Directors is made up of industry veterans that have successfully led publicly held medical companies with sustained growth and profitability. We are pleased to present:
Michael Redmond – CEO and Chairman of the Board of Directors: Commercial leadership experience in public medical device companies including Abbott Laboratories, Bioject Inc. and KMC Medical Systems Inc. Previous experience as CEO of publicly held Parallax Health Sciences Inc.
Jeff Conroy – Director: Jeff is currently CEO of Embody Inc. Jeff brings 30 years experience in forming strategic alliances and commercializing products in the Life Sciences and Medical Device markets. As founder of both Adjuvant Partners and Windward Investments, Jeff has provided advisory services for turn around, strategy and licensing to pharmaceutical, biotech and medical device companies since 1999. Jeff has also served as the Principle Licensing Officer for Especificos Stendhal S.A. de C.V. a Latin America specialty pharmaceutical company where he completed over $4B in licensing and partnership arrangements. Jeff is a Director and past Chairman of the Virginia Biotech Association.